dc.contributor.author
Penack, Olaf
dc.contributor.author
Peczynski, Christophe
dc.contributor.author
Mohty, Mohamad
dc.contributor.author
Yakoub-Agha, Ibrahim
dc.contributor.author
Camara, Rafael de la
dc.contributor.author
Glass, Bertram
dc.contributor.author
Duarte, Rafael F.
dc.contributor.author
Kröger, Nicolaus
dc.contributor.author
Schoemans, Hélène
dc.contributor.author
Koenecke, Christian
dc.contributor.author
Peric, Zinaida
dc.contributor.author
Basak, Grzegorz W.
dc.date.accessioned
2023-08-10T15:34:52Z
dc.date.available
2023-08-10T15:34:52Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/40443
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-40164
dc.description.abstract
Risk assessment of allogeneic hematopoietic cell transplantation (allo-HCT) is hindered by the lack of current data on comorbidities and outcome. The EBMT identified 38,760 allo-HCT recipients with hematologic malignancies transplanted between 2010 and 2018 from matched sibling and unrelated donors with a full data set of pre-existing comorbidities. Multivariate analyses using the Cox proportional-hazards model including known risk factors for non-relapse mortality (NRM) were performed. We found that pre-existing renal comorbidity had the strongest association with NRM (hazard ratio [HR] 1.85 [95% CI 1.55-2.19]). In addition, the association of multiple pre-existing comorbidities with NRM was significant, including diabetes, infections, cardiac comorbidity, and pulmonary comorbidity. However, the HR of the association of these comorbidities with NRM was relatively low and did not exceed 1.24. Consequently, the risk of NRM was only moderately increased in patients with a high hematopoietic cell transplantation comorbidity index (HCT-CI) >= 3 (HR 1.34 [1.26-1.42]). In the current EBMT population, pre-existing non-renal comorbidities determined NRM after allo-HCT to a much lesser extent as compared with the underlying HCT-CI data. Improvements in management and supportive care as well as higher awareness based on the use of HCT-CI may have contributed to this favorable development.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
allogeneic hematopoietic cell transplantation (allo-HCT)
en
dc.subject
comorbidities
en
dc.subject
European Society for Blood and Marrow Transplantation (EBMT)
en
dc.subject
risk assessment
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1038/s41409-021-01502-8
dcterms.bibliographicCitation.journaltitle
Bone Marrow Transplantation
dcterms.bibliographicCitation.number
2
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.pagestart
183
dcterms.bibliographicCitation.pageend
190
dcterms.bibliographicCitation.volume
57
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
34718346
dcterms.isPartOf.issn
0268-3369
dcterms.isPartOf.eissn
1476-5365